30.5 USD
-0.87 (-2.77%)
30.5 USD
0 (0%)
Taking everything into account, PRCT scores 4 out of 10 in our fundamental rating. PRCT was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While PRCT seems to be doing ok healthwise, there are quite some concerns on its profitability. PRCT is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
- In the past year PRCT has reported negative net income.
- PRCT had a negative operating cash flow in the past year.
- PRCT had negative earnings in each of the past 5 years.
- In the past 5 years PRCT always reported negative operating cash flow.
1.2 Ratios
- The Return On Assets of PRCT (-16.53%) is comparable to the rest of the industry.
- With a decent Return On Equity value of -22.24%, PRCT is doing good in the industry, outperforming 60.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.53% | ||
| ROE | -22.24% | ||
| ROIC | N/A |
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 64.55%, PRCT is in the better half of the industry, outperforming 68.11% of the companies in the same industry.
- PRCT's Gross Margin has improved in the last couple of years.
- PRCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
2. Health
2.1 Basic Checks
- PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for PRCT has been increased compared to 1 year ago.
- The number of shares outstanding for PRCT has been increased compared to 5 years ago.
- The debt/assets ratio for PRCT has been reduced compared to a year ago.
2.2 Solvency
- PRCT has an Altman-Z score of 7.05. This indicates that PRCT is financially healthy and has little risk of bankruptcy at the moment.
- PRCT has a better Altman-Z score (7.05) than 83.78% of its industry peers.
- A Debt/Equity ratio of 0.14 indicates that PRCT is not too dependend on debt financing.
- PRCT's Debt to Equity ratio of 0.14 is fine compared to the rest of the industry. PRCT outperforms 62.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 7.05 |
ROIC/WACCN/A
WACC9.9%
2.3 Liquidity
- A Current Ratio of 8.44 indicates that PRCT has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 8.44, PRCT belongs to the top of the industry, outperforming 89.19% of the companies in the same industry.
- PRCT has a Quick Ratio of 7.20. This indicates that PRCT is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of PRCT (7.20) is better than 89.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.44 | ||
| Quick Ratio | 7.2 |
3. Growth
3.1 Past
- PRCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
- The Revenue has grown by 50.07% in the past year. This is a very strong growth!
- PRCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.20% yearly.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
Revenue 1Y (TTM)50.07%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%42.76%
3.2 Future
- PRCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.88% yearly.
- Based on estimates for the next years, PRCT will show a very strong growth in Revenue. The Revenue will grow by 26.01% on average per year.
EPS Next Y12.5%
EPS Next 2Y15.69%
EPS Next 3Y18%
EPS Next 5Y15.88%
Revenue Next Year46.32%
Revenue Next 2Y37.63%
Revenue Next 3Y33.25%
Revenue Next 5Y26.01%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PRCT. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRCT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- PRCT's earnings are expected to grow with 18.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.69%
EPS Next 3Y18%
5. Dividend
5.1 Amount
- No dividends for PRCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
30.5
-0.87 (-2.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners106.65%
Inst Owner Change0.1%
Ins Owners4.23%
Ins Owner Change13.22%
Market Cap1.70B
Revenue(TTM)299.91M
Net Income(TTM)-84.58M
Analysts82
Price Target53.81 (76.43%)
Short Float %11.39%
Short Ratio4.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.37%
Min EPS beat(2)9.47%
Max EPS beat(2)17.27%
EPS beat(4)3
Avg EPS beat(4)8.01%
Min EPS beat(4)-4.69%
Max EPS beat(4)17.27%
EPS beat(8)6
Avg EPS beat(8)5.92%
EPS beat(12)8
Avg EPS beat(12)3.91%
EPS beat(16)10
Avg EPS beat(16)4.32%
Revenue beat(2)2
Avg Revenue beat(2)1.27%
Min Revenue beat(2)0.93%
Max Revenue beat(2)1.61%
Revenue beat(4)4
Avg Revenue beat(4)1.49%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.23%
Revenue beat(8)8
Avg Revenue beat(8)3.05%
Revenue beat(12)11
Avg Revenue beat(12)2.51%
Revenue beat(16)15
Avg Revenue beat(16)5.35%
PT rev (1m)-1.82%
PT rev (3m)-20.62%
EPS NQ rev (1m)0.1%
EPS NQ rev (3m)-21.81%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)-1.64%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-2.32%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.68 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.48 | ||
| P/tB | 4.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS5.37
BVpS6.81
TBVpS6.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.53% | ||
| ROE | -22.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.55% | ||
| FCFM | N/A |
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.14 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 141.51% | ||
| Cap/Sales | 2.89% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.44 | ||
| Quick Ratio | 7.2 | ||
| Altman-Z | 7.05 |
F-Score6
WACC9.9%
ROIC/WACCN/A
Cap/Depr(3y)279.88%
Cap/Depr(5y)173.09%
Cap/Sales(3y)8%
Cap/Sales(5y)5.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
EPS Next Y12.5%
EPS Next 2Y15.69%
EPS Next 3Y18%
EPS Next 5Y15.88%
Revenue 1Y (TTM)50.07%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%42.76%
Revenue Next Year46.32%
Revenue Next 2Y37.63%
Revenue Next 3Y33.25%
Revenue Next 5Y26.01%
EBIT growth 1Y13.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.23%
EBIT Next 3Y32.28%
EBIT Next 5Y29.2%
FCF growth 1Y36.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.44%
OCF growth 3YN/A
OCF growth 5YN/A
PROCEPT BIOROBOTICS CORP / PRCT FAQ
What is the fundamental rating for PRCT stock?
ChartMill assigns a fundamental rating of 4 / 10 to PRCT.
What is the valuation status for PRCT stock?
ChartMill assigns a valuation rating of 0 / 10 to PROCEPT BIOROBOTICS CORP (PRCT). This can be considered as Overvalued.
What is the profitability of PRCT stock?
PROCEPT BIOROBOTICS CORP (PRCT) has a profitability rating of 2 / 10.
What is the financial health of PROCEPT BIOROBOTICS CORP (PRCT) stock?
The financial health rating of PROCEPT BIOROBOTICS CORP (PRCT) is 6 / 10.